Sydney A. Lash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sydney A. Lash has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Dale P. Sandler
Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, Durham, NC, USA
5 shared publications - Katie M. O'Brien
Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, USA
5 shared publications - Mandy Goldberg
Epidemiology Branch National Institute of Environmental Health Sciences Research Triangle Park North Carolina USA
5 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Supplementary Table S1 shows the hazard ratios and 95% confidence intervals for the associations of timing of thelarche and menarche jointly with incident ovarian cancer in the Sister Study cohort (n = 40,809 participants).
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Supplementary Table S1 shows the hazard ratios and 95% confidence intervals for the associations of timing of thelarche and menarche jointly with incident ovarian cancer in the Sister Study cohort (n = 40,809 participants).
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Background:Pubertal milestones such as menarche (first period) and thelarche (onset of breast development) are markers of hormonal changes that may be relevant to the hormonal etiology of ovarian cancer. Prior studies of the association between age at menarche and ovarian cancer risk have been inconsistent, whereas age at thelarche has not been examined in relation to ovarian cancer incidence.Methods:With data from 40,809 women in the Sister Study, we used multivariable-adjusted Cox proportional hazards regression to estimate HRs and 95% confidence intervals (CI) for associations of self-reported ages at thelarche and menarche with incident ovarian cancer, both overall and by histotype.Results:During a median follow-up of 13.3 years, 291 women reported a diagnosis of ovarian cancer. Ages at thelarche (HR = 0.94; 95% CI, 0.87–1.02 per 1-year older) and menarche (HR = 0.99; 95% CI, 0.91–1.07 per 1-year older) were not associated with ovarian cancer overall. Although imprecise, HRs suggested a possible inverse association of ages at thelarche (HR = 0.71; 95% CI, 0.48–1.04) and menarche (HR = 0.79; 95% CI, 0.59–1.04) with the incidence of clear-cell tumors.Conclusions:Ages at thelarche and menarche were not associated with ovarian cancer incidence overall.Impact:Though our results do not provide clear evidence of associations of pubertal timing with ovarian cancer incidence, possible associations of earlier thelarche and menarche with increased incidence of ovarian clear-cell carcinoma may warrant further investigation, especially considering secular trends toward earlier thelarche.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Background:Pubertal milestones such as menarche (first period) and thelarche (onset of breast development) are markers of hormonal changes that may be relevant to the hormonal etiology of ovarian cancer. Prior studies of the association between age at menarche and ovarian cancer risk have been inconsistent, whereas age at thelarche has not been examined in relation to ovarian cancer incidence.Methods:With data from 40,809 women in the Sister Study, we used multivariable-adjusted Cox proportional hazards regression to estimate HRs and 95% confidence intervals (CI) for associations of self-reported ages at thelarche and menarche with incident ovarian cancer, both overall and by histotype.Results:During a median follow-up of 13.3 years, 291 women reported a diagnosis of ovarian cancer. Ages at thelarche (HR = 0.94; 95% CI, 0.87–1.02 per 1-year older) and menarche (HR = 0.99; 95% CI, 0.91–1.07 per 1-year older) were not associated with ovarian cancer overall. Although imprecise, HRs suggested a possible inverse association of ages at thelarche (HR = 0.71; 95% CI, 0.48–1.04) and menarche (HR = 0.79; 95% CI, 0.59–1.04) with the incidence of clear-cell tumors.Conclusions:Ages at thelarche and menarche were not associated with ovarian cancer incidence overall.Impact:Though our results do not provide clear evidence of associations of pubertal timing with ovarian cancer incidence, possible associations of earlier thelarche and menarche with increased incidence of ovarian clear-cell carcinoma may warrant further investigation, especially considering secular trends toward earlier thelarche.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Supplementary Table S2 shows the hazard ratios and 95% confidence intervals for the associations of age at thelarche and time from thelarche to menarche (pubertal tempo) with incident ovarian cancer among participants with age at thelarche at least one year before age at menarche (n = 18,679 participants).
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Supplementary Table S2 shows the hazard ratios and 95% confidence intervals for the associations of age at thelarche and time from thelarche to menarche (pubertal tempo) with incident ovarian cancer among participants with age at thelarche at least one year before age at menarche (n = 18,679 participants).
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Supplementary Figure S1 shows a flow chart of eligible Sister Study participants for this analysis.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Supplementary Figure S1 shows a flow chart of eligible Sister Study participants for this analysis.
- 24 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1669-1672
Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Background: Pubertal milestones such as menarche (first period) and thelarche (onset of breast development) are markers of hormonal changes that may be relevant to the hormonal etiology of ovarian cancer. Prior studies of the association between age at menarche and ovarian cancer risk have been inconsistent, whereas age at thelarche has not been examined in relation to ovarian cancer incidence. Methods: With data from 40,809 women in the Sister Study, we used multivariable-adjusted Cox proportional hazards regression to estimate HRs and 95% confidence intervals (CI) for associations of self-reported ages at thelarche and menarche with incident ovarian cancer, both overall and by histotype. Results: During a median follow-up of 13.3 years, 291 women reported a diagnosis of ovarian cancer. Ages at thelarche (HR = 0.94; 95% CI, 0.87–1.02 per 1-year older) and menarche (HR = 0.99; 95% CI, 0.91–1.07 per 1-year older) were not associated with ovarian cancer overall. Although imprecise, HRs suggested a possible inverse association of ages at thelarche (HR = 0.71; 95% CI, 0.48–1.04) and menarche (HR = 0.79; 95% CI, 0.59–1.04) with the incidence of clear-cell tumors. Conclusions: Ages at thelarche and menarche were not associated with ovarian cancer incidence overall. Impact: Though our results do not provide clear evidence of associations of pubertal timing with ovarian cancer incidence, possible associations of earlier thelarche and menarche with increased incidence of ovarian clear-cell carcinoma may warrant further investigation, especially considering secular trends toward earlier thelarche.
- 24 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1669-1672
Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort
Background: Pubertal milestones such as menarche (first period) and thelarche (onset of breast development) are markers of hormonal changes that may be relevant to the hormonal etiology of ovarian cancer. Prior studies of the association between age at menarche and ovarian cancer risk have been inconsistent, whereas age at thelarche has not been examined in relation to ovarian cancer incidence. Methods: With data from 40,809 women in the Sister Study, we used multivariable-adjusted Cox proportional hazards regression to estimate HRs and 95% confidence intervals (CI) for associations of self-reported ages at thelarche and menarche with incident ovarian cancer, both overall and by histotype. Results: During a median follow-up of 13.3 years, 291 women reported a diagnosis of ovarian cancer. Ages at thelarche (HR = 0.94; 95% CI, 0.87–1.02 per 1-year older) and menarche (HR = 0.99; 95% CI, 0.91–1.07 per 1-year older) were not associated with ovarian cancer overall. Although imprecise, HRs suggested a possible inverse association of ages at thelarche (HR = 0.71; 95% CI, 0.48–1.04) and menarche (HR = 0.79; 95% CI, 0.59–1.04) with the incidence of clear-cell tumors. Conclusions: Ages at thelarche and menarche were not associated with ovarian cancer incidence overall. Impact: Though our results do not provide clear evidence of associations of pubertal timing with ovarian cancer incidence, possible associations of earlier thelarche and menarche with increased incidence of ovarian clear-cell carcinoma may warrant further investigation, especially considering secular trends toward earlier thelarche.